Healthcare
True North buys another unit from India's Glenmark
Mumbai-based Glenmark Pharmaceuticals has agreed to sell its gynecology operations in India and Nepal to a True North portfolio company for $16.2 million.
Green Pine leads Series B for Chinese gene testing player
Chinese gene testing business AmCare Genomics Lab has raised RMB110 million ($16 m) in Series B funding led by Green Pine Capital Partners. This comes four months after the company closed an extended Series A round of RMB30 million.
AVCJ Awards 2019: Exit of the Year - IPO: Innovent Biologics
Innovent Biologics has set a new standard for Chinese biotech, securing an innovative drug development tie-up with Eli Lilly and then completing a successful Hong Kong listing
China's I-Mab falls on US debut after $104m IPO
China-based I-Mab Biopharma traded as much as 12% lower than initial pricing following the private equity-backed company’s $104 million IPO in the US.
Ankur achieves first close on second India VC fund
Ankur Capital, an Indian early-stage investor focused on healthcare and agriculture technology investments, has reached a first close of INR2.4 billion ($33 million) on its second fund.
Zhiyun raises $144m for chronic disease management platform
Zhiyun Health, a Chinese online healthcare services provider, has raised more than RMB1 billion ($144 million) across two rounds. It describes the investment as the largest private funding event globally in the chronic disease management space.
China's Transcenta secures $100m funding round
Transcenta Holding, a Chinese biotech company formed last year through the merger of MabSpace Bioscience and Hangzhou Just Biotherapeutics (HJB), has raised $100 million in an extended Series B funding round.
Chinese drug developer wins General Atlantic backing
General Atlantic has led a $69 million Series D round of funding for Adagene, a Chinese drug developer with one cancer treatment currently in phase one clinical trials in China and the US.
EQT backs Southeast Asia hospital operator
EQT Partners has confirmed an investment of undisclosed size in Health Management International (HMI), a hospital operator with a presence in Singapore, Malaysia, and Indonesia.
China’s CF PharmTech raises $90m Series E
CF PharmTech, a Chinese devices maker focused on respiratory health, has raised $90 million in Series E funding led by local private equity investor New Alliance Capital.
Everstone backs US, India-based generics developer
The Everstone Group has agreed to invest $50 million in Slayback Pharma, a developer of generic and specialty drugs with a presence in India and the US.
India's True North makes $75m biosimilars bet
True North has invested INR5.36 billion ($74.6 million) in the biosimilars business of India-listed pharmaceuticals giant Biocon.
Chinese genetic testing player secures $115m round
Geneseeq, a Chinese genetic testing company that focuses on treatments for cancer, has raised RMB800 million ($115 million) in a funding round led by state-owned China Reform Holding Corporation.
Chinese biopharma player secures $100m Series B
Elpiscience, a Shanghai-based biopharmaceutical company has completed a $100 million Series B round of funding led by specialist healthcare GP Hyfinity Investments.
Singapore medical tech start-up raises $40 million
Awak Technologies, a Singaporean start-up that makes wearable dialysis treatment devices, has raised $40 million co-led by Vickers Venture Partners and an unnamed medical technology company.
China's KeChow Pharma gets $45m Series C
Shanghai Kechow Pharma, a Chinese small molecule targeted drug developer, has raised a $45 million Series C round led by Decheng Capital.
General Atlantic promotes China healthcare head
Lefei Sun, who helped establish and now leads General Atlantic’s healthcare and life sciences business in China, has been promoted to managing director.
Deal focus: EQT fulfills Laobaixing's prescription
EQT spent 11 years helping Chinese pharmacy chain Laobaixing evolve from large-format laggard into a focused and efficient operator that meets the needs of modern customers. It has now exited with a 7.7x return
Local GPs commit $71m to China biotech player
EOC Pharma, a Chinese biotech developer focused on cancer treatments, has closed a RMB500 million ($71 million) Series C round raised from a group of local private equity investors.
Chinese biopharma start-up raises $43m Series B
Chinese cancer and autoimmune disease therapy developer Clover Biopharmaceuticals has raised a $43 million Series B round led by local VC Lapam Capital and US private equity firm Delos Capital.
China’s Loyal Valley closes second US dollar fund at $465m
China’s Loyal Valley Capital has closed its second US dollar-denominated fund at $465 million. The target was $400 million with a hard cap of $440 million.
FountainVest, Primavera invest $557m in China pharmacy chain
FountainVest Partners and Primavera Capital have paid $557 million for a 24.78% stake in Chinese pharmacy chain Laobaixing. It will provide a full exit for EQT Partners.
Singapore dental products start-up receives $13m Series A
Zenyum, a Singapore-based manufacturer of 3D-printed cosmetic dental products, has raised $13.6 million in Series A funding from RTP Global, Sequoia Capital India, TNB Aura, and Seeds Capital.
Japan health tech player SmartScan gets $10m Series A
SmartScan, a Japanese medical technology supplier focused on software for diagnostics equipment, has raised a JPY1.3 billion ($10.3 million) Series A round from domestic VCs.
